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Background: Hsp31 is a multifunctional cellular stress response protein.
Results: Hsp31 is a stress-inducible chaperone that has substoichiometric activity on a wide spectrum of substrates, including
prions and the non-physiological client, -synuclein.
Conclusion: Hsp31 protects cells from -synuclein-mediated toxicity via chaperone activity and independently from enzymatic
activity and autophagy.
Significance: This is the first characterization of the early acting and wide ranging chaperone activity of Hsp31.

The Saccharomyces cerevisiae heat shock protein Hsp31 is a
stress-inducible homodimeric protein that is involved in diauxic
shift reprogramming and has glyoxalase activity. We show that
substoichiometric concentrations of Hsp31 can abrogate aggregation of a broad array of substrates in vitro. Hsp31 also modulates
the aggregation of -synuclein (Syn), a target of the chaperone
activity of human DJ-1, an Hsp31 homolog. We demonstrate that
Hsp31 is able to suppress the in vitro fibrillization or aggregation of
Syn, citrate synthase and insulin. Chaperone activity was also
observed in vivo because constitutive overexpression of Hsp31
reduced the incidence of Syn cytoplasmic foci, and yeast cells
were rescued from Syn-generated proteotoxicity upon Hsp31
overexpression. Moreover, we showed that Hsp31 protein levels
are increased by H2O2, in the diauxic phase of normal growth conditions, and in cells under Syn-mediated proteotoxic stress. We
show that Hsp31 chaperone activity and not the methylglyoxalase
activity or the autophagy pathway drives the protective effects. We
also demonstrate reduced aggregation of the Sup35 prion domain,
PrD-Sup35, as visualized by fluorescent protein fusions. In addition, Hsp31 acts on its substrates prior to the formation of large
aggregates because Hsp31 does not mutually localize with prion
aggregates, and it prevents the formation of detectable in vitro
Syn fibrils. These studies establish that the protective role of
Hsp31 against cellular stress is achieved by chaperone activity that
intervenes early in the protein misfolding process and is effective
on a wide spectrum of substrate proteins, including Syn and prion
proteins.
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Heat shock proteins (HSPs)5 protect living cells against environmental stress and promote cell survival. This function is
evolutionarily conserved throughout different organisms. HSPs
interact with misfolded proteins and process them using several
mechanisms, including chaperone functions to prevent misfolded protein aggregation, unraveling protein aggregates, or
carrying out protease functions to eliminate irreversibly damaged proteins. The effect of HSPs in maintaining cellular homeostasis throughout the protein folding process is essential to
preventing diseases associated with protein misfolding and
aggregation, such as Alzheimer disease, Parkinson disease (PD),
and Huntington disease. HSPs involved in counteracting these
protein inclusions are currently under intensive study (1).
Among the neurodegenerative diseases, PD is the second
most common neurodegenerative disorder that occurs in
elderly individuals 50 years or older, and no cure is currently
known (2, 3). High levels of reactive oxygen species (ROS), dysfunctional mitochondria, and the aggregation of Syn are
observed in PD (4 – 8). DJ-1, a gene linked to familial forms of
PD, has been found to be involved in oxidative insults, proteasome degradation, and protein folding and is the focus of extensive studies to understand its functions in regulating levels of
Syn aggregation (9 –14).
Human DJ-1, yeast Hsp31 (YDR533c), and Escherichia coli
Hsp31 (hchA or yedU) are members of the DJ-1/PfpI/ThiJ
superfamily (10, 15, 16). Crystal structures of Hsp31 show that
it contains a cysteine catalytic triad that is conserved in the
DJ-1/PfpI/ThiJ family (17, 18). E. coli hchA is a close ortholog
with yeast Hsp31, and they share superimposable active sites in
each monomer, but their quaternary structures appear to be
different (17, 19). This protein family is of biomedical importance due to the role these proteins play in chaperone-like and
5

The abbreviations used are: HSP, heat shock protein; Syn, -synuclein; PD,
Parkinson disease; ROS, reactive oxygen species; MGO, methylglyoxal; SD,
synthetic dextrose; CS, citrate synthase; SC, synthetic complete; SDD-AGE,
semidenaturing detergent-agarose gel electrophoresis; PrD, prion-forming domain(s); CFP, cyan fluorescence protein; EYFP, enhanced yellow fluorescence protein; DsRed, red fluorescence protein from Discosoma sp.;
MORF, yeast movable ORF tag.
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TABLE 1
Yeast strains
Strain

Genotype

Source/Reference

BY4741
W303-1A
W303-hsp31
W303-HSP31-9myc
W303–1xSyn
W303–2xSyn

MATa his3, leu2, met15, ura3, ARL1, GCS1, ARL3, ARF3, YPT6, IMH1, SYS1, GAS1
MATa can1-100 his3-11,15 leu2-3, 112 trp1-1 ura3-1 ade2-1
W303-1A hsp31:natMX
W303-1A HSP31-9myc::kanMX
W303 GAL-Syn-YFP at URA3 or TRP1 loci
W303 GAL-Syn-YFP at URA3 GAL-Syn-CFP at TRP1 loci

Invitrogen
R. Rothstein
This study
This study
J-C. Rochet (75, 76)
J-C. Rochet

cytoprotective activities (15, 19). Despite the shared structural
similarity, this family can be further subcategorized into three
classes according to the structural and functional properties of
the proteins or into five subclasses by protein sequence alignments (15, 19). The cellular functions of DJ-1 and E. coli hchA
have been characterized, and their multifunctional roles in
mediating oxidative stress, chaperone-like activity, methylglyoxalase activity, and cytoprotection have been described (10,
15, 16, 19). There has been limited characterization of the cellular functions of Hsp31, but several recent studies have demonstrated that it has glyoxylase activity (20), chaperone activity
(21), and a role in autophagy (22).
Yeast PD models have been used to study the mechanism of
the sporadic and familial forms of PD (23–25). We are extending the utility of these yeast models by investigating the biological activities of yeast Hsp31. Hsp31 appears to be a stressinducible 26-kDa protein based on several large scale studies
indicating that yeast Hsp31 is up-regulated when cells are
exposed to environmental stress (26 –29). For example, Hsp31
was implicated to be protective against ROS because an hsp31
strain was more sensitive to oxidative stress (26). HchA has
structural similarity to Hsp31 and is established as having chaperone activities, suggesting that Hsp31 could act similarly; however, this has yet to be confirmed. The evidence for a role in
stress response, possible chaperone activity, methylglyoxalase
activity, and cross-talk with the autophagy pathway led us to
investigate these activities of Hsp31 in modulating Syn cytoplasmic foci formation and prion aggregation. Syn is not present in yeast and hence is a non-physiological substrate, but it
mimics physiologically relevant activity based on its localization and toxicity, and we capitalized on these features. Therefore, we designed a set of biochemical, genetic, and cell biology
experiments to demonstrate the role of Hsp31 chaperone activity in protecting cells from Syn-mediated cytotoxicity. We
also demonstrate that Hsp31 has methylglyoxalase activity that
converts methylglyoxal (MGO) substrate to D-lactate, but this
enzyme activity is not essential for protecting against Synmediated cytotoxicity.

Experimental Procedures
Yeast Cell Growth Conditions
Yeast media were prepared according to Amberg et al. (30).
Liquid yeast extract/peptone dextrose medium contained
Bacto yeast extract (1%; Fisher), Bacto peptone (2%; Fisher), and
glucose (2%; Fisher). Synthetic dextrose (SD) minimum liquid
medium was made of 0.17% Difco yeast nitrogen base (without
amino acids) and 2% glucose and supplemented with necessary
amino acids for auxotrophic strains needed at concentrations
described previously (30). Solid medium plates were made
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41
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with the same components of liquid medium plus 2% agar
(Fisher). To express galactose-inducible proteins, 2% raffinose
(Affymetrix, Cleveland, OH) and 2% galactose (Affymetrix)
were used to replace glucose. Fractions of culture were obtained
at designated times to monitor the cell fitness and protein levels
by A600 and immunoblotting, respectively.
All of the yeast strains were grown at 30 °C in 2% glucose
minimal medium overnight. Strains were diluted to A600 of 0.2
and grown in minimal medium switching the carbon source
with 2% raffinose for the overnight period. Cultures were normalized to A600 of 0.8, and 5-fold serial dilutions were aliquoted
onto the respected appropriate dropout plate containing 2%
glucose or galactose. Plates were incubated at 30 °C for 2–3
days.
Yeast Strain Construction
Yeast strains used in this study are listed in Table 1. The
hsp31 and atg8 deletions were generated in W303-1A or in a
strain expressing one or two copies Syn fused to fluorescent
proteins (CFP and YFP) using the primers listed in Table 2. The
nat (nourseothricin N-acetyltransferase) gene flanked by
Hsp31 homology regions was obtained by PCR with 70-nucleotide-long forward primer and reverse primer. The primers
consisted of 20 nucleotides for amplifying the nat gene from
pFA6a-natNT2 (Euroscarf) and 50 nucleotides immediately
preceding the HSP31 or ATG8 start codon or after the stop
codon. The amplified product was integrated into W303 Synexpressing strains at ChrIV:1502160 to 1501447, as described
previously (31). For double knock-out hsp31 atg8 strain, the
kanMX4 resistance cassette was used to delete Hsp31, and then
the natMX4 resistance cassette was used for deletion of ATG8.
Hsp31–9myc Tagging
We endogenously tagged HSP31 with the 9myc epitope using
a PCR-based integration (12). The pYM20 plasmid was used as
a template, and primers were used to obtain PCR product with
HSP31 genomic flanking followed by transformation into
W303 and W303 Syn-CFP  Syn-YFP strains. The transformants were selected on media containing hygromycin B (300
mg/liter), and correct integration was verified by PCR using
primers spanning the integration junctions and by DNA
sequence analysis.
DNA Manipulation
The plasmids used in this study are listed in Table 3. Plasmid
BG1805 was linearized with NdeI (New England Biolabs, Ipswich, MA) and cloned into pDONR221 (Invitrogen) with BP
Clonase (Invitrogen) with the method provided by the manufacturer. Hsp31 was shuttled into pAG415-GPD-ccdB-DsRed
JOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 2
Primers
Gene/Description
HSP31 deletion
9myc tag of HSP31
HSP31
ATG8 deletion
HSP31 mutation C138D
ATG8 deletion diagnostic
HSP31 9myc tag diagnostic
HSP31 deletion diagnostic

Forward

Reverse

AAGTACTTCCCACTGGCTAATTACACAGATAAAACTCAAACAAA
TTTATAATGACATGGAGGCCCAGAATACCC
TCTGCGCACTCCACTGCCGTAAGATCCATCGACGCTTTAAAAA
ACCGTACGCTGCAGGTCGAC
AAACTCGAGATGGCCCCAAAAAAAGTTTTACTCGC
AGTTGAGAAAATCATAATAAAATAATTACTAGAGACATGACAT
GGAGGCCCAGAATACCC
GTTGATCACGGTCCTGCTATTTTTGATGGG
GGGAACCATTAAAGGTTGAGGAGG
ACAGAGAATTAACGTTACTCATTCC
TTCGTGGTCGTCTCGTACTC

CTTACATCTATATAGTAGTACAAAGGAAATTCTAATTATC
AACCTTTGGCTCACAGTATAGCGACCAGCATTCAC
TCCTTACATCTATATAGTAGTACAAAGGAAATTCTAATTAT
CAACCTTTGGCTCAATCGATGAATTCGAGCTCG
TTTGCTAGCTCAGTTTTTTAAAGCGTCGATGGATCTTAC
CGATTTTAGATGTTAACGCTTCATTTCTTTTCATATAAAA
GACTACAGTATAGCGACCAGCATTCAC
GTGATCAACAGCTGCGACAACACCACCG
GTAAACATTCTTATACTGGAACA
ATATTTGGATATTGGGGAAACACAT
GCAGGGCATGCTCATGTAGA

TABLE 3
Plasmids
Plasmids

Type of plasmid

BG1805 HSP31-MORF
Yeast, 2 
pGEX6P-1 HSP31
E. coli
pESC-Leu
Yeast, 2 
pESC-Leu myc-HSP31
Yeast, 2 
pNT-hchA His6-hchA
E. coli
E. coli
pT7 Syn
pAG415-GPD-HSP31-DsRed
Yeast, CEN
pAG415-ccdB-DsRed
Yeast, CEN
pAG424-GAL-PrD-Sup35-EYFP Yeast, 2 
p2HG-GPD-HSP104
Yeast
p2HG-GPD
Yeast

Source/Reference
Gelperin et al. (77)
This study
Agilent Technologies
This study
Sastry et al. (78)
Paleologou et al. (33)
This study
Alberti et al. (39)
Alberti et al. (79)
J-C. Rochet
J-C. Rochet

(Addgene, Cambridge, MA) (32) from pDONR221 with LR
Clonase (Invitrogen) to produce pAG415-GPD-HSP31-DsRed.
Both DJ-1 and Hsp31 were cloned into BamHI/XhoI sites of
pGEX 6p-1. pESC-Leu myc-HSP31 was constructed by cloning
at the XhoI/NheI sites. The HSP31 gene was amplified from
yeast genomic DNA. The Hsp31 C138D mutant was prepared
by PCR amplification using pAG415-GPD-HSP31-DsRed as
template and the set of primers listed in Table 2. Each successfully mutated insert was sequenced to confirm the mutation.
Antibodies and Immunoblotting
To determine protein expression, yeast cells were collected
by centrifuging at 5,000 rpm, and pellets were resuspended in
extraction buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 4 mM
MgCl2, 5 mM DTT). Glass beads (Sigma) were added into the
mixture, which was vortexed 5 times for 10 s each, plus 1-min
intervals on ice. Clear crude protein lysate was obtained by
spinning down the cell debris at 1,000  g at 4 °C for 10 min.
The SDS-PAGE loading dye (4% SDS, 40% glycerol, 0.02% bromphenol blue, Tris-Cl, pH 6.8) was added to the supernatant,
and samples were boiled, followed by SDS-PAGE and immunoblotting with antibodies. Monoclonal anti-Myc and anti--actin antibody were purchased from Sigma-Aldrich. Monoclonal
anti-Syn was obtained from BD Biosciences. Antibodies were
used to detect expression of Hsp104 (ab69549, Abcam), Hsp70
(SPA-82, Stressgen); DsRed (Sc-33353, Santa Cruz Biotechnology, Inc.), and GFP (anti-GFP, Roche Applied Science).
Protein Purification
BY4741 harboring yeast Hsp31 expression plasmid from the
yeast moveable ORF collection (33) (Thermo Fisher Scientific)
was used to express and purify the protein (33). We did not see
any evidence of co-purifying proteins on SDS-polyacrylamide
gels and observed similar high activity from protein purified
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under high salt conditions, which minimizes contaminant copurifying proteins. Human DJ-1 was encoded in pGEX 6p-1
(GE Healthcare), hchA was encoded in pNT-hchA, and Syn
was expressed from the pT7 plasmid. The protein expression
and purification was described previously (34 –36). Briefly,
constructs were transformed into BL21 (DE3) cells. The transformants were grown to an A600 of 0.4 – 0.6 in LB medium supplemented with 100 g/ml ampicillin at 37 °C, and isopropyl
-D-1-thiogalactopyranoside (1 mM final concentration) was
added to induce protein expression. After 3 h of induction at
37 °C, cells were harvested by centrifugation at 2,000  g and
resuspended in lysis buffer (25 mM KPi, pH 7.0, 200 mM KCl)
containing protease inhibitor mixture set IV (Calbiochem).
Crude protein was prepared by sonicating cells and clarifying
the lysate by centrifugation at 10,000  g for 10 min. GSTtagged DJ-1 was immobilized by glutathione-agarose resin
(Thermo Scientific), and DJ-1 was eluted by cleaving from the
GST tag with PreScission Protease (GE Healthcare) (2 units of
protease for every 100 g of tagged DJ-1), leaving a linker
amino acid sequence: NPAFLYKVVDVSRHHHGRIFYPYDVPDYAGLEVLFQ.
Sedimentation velocity ultracentrifugation was performed
with two different Hsp31 concentrations (34 and 17 M) and
run at 50,000 rpm in a Beckman Coulter XLA centrifuge (Beckman Coulter, Fullerton, CA). The sedimentation coefficients
and apparent molecular weights were calculated from size distribution analyses (c(s)) using SEDFIT (37).
His6-hchA was immobilized by HIS-Select nickel affinity
gel (Sigma-Aldrich) and eluted with elution buffer (Tris-Cl, pH
7.5, 250 M imidazole). The purity of proteins was determined
by SDS-PAGE followed by Coomassie Blue staining, and concentrations were determined by a Micro BCA protein assay kit
(Thermo Scientific, Waltham MA). The Syn protein for in
vitro fibrillization assays was purified by expressing pT7-7 plasmid containing human Syn cDNA (provided by R. Jakes and
M. Goedert, Medical Research Council, Cambridge, UK) with
isopropyl -D-1-thiogalactopyranoside in BL21 (DE3) for 4 h of
incubation at 37 °C. The cells were harvested and resuspended
in 10 mM Tris-Cl, pH 8, 1 mM EDTA, 1 mM PMSF at 1⁄20 culture
volume. The cell lysate was obtained by one round of freezethawing and French press treatment, and protein was partially
purified and enriched by two rounds of ammonium sulfate precipitation (30% saturation first and then 50% saturation at 0 °C).
The pellets were resuspended and boiled in 10 mM Tris-HCl,
pH 7.4, for 5 min. The insoluble protein was removed by centrifugation, and the supernatant was filtered using a 0.22-m
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filter. The filtered fraction of the protein was applied to a
DEAE-Sepharose FF column (GE Healthcare) with 10 mM TrisHCl, pH 7.4, and eluted with 0 –500 mM NaCl over 100 min.
The fractions containing Syn were dialyzed against 10 mM
NH4HCO3 and lyophilized. The protein was 95% pure based
on Coomassie Blue staining with SDS-PAGE.
Chaperone Activity Aggregation Suppression Assays
Thermal Aggregation Assay of Citrate Synthase (CS)—CS
aggregation suppression assay was performed according to the
procedures described previously (38). Briefly, CS (porcine CS,
Sigma), Hsp31, DJ-1, and hchA were buffer-exchanged into 40
mM Hepes-KOH (pH 7.5). Proteins were diluted to concentrations ranging from 0.1 to 0.6 M in a 500-l reaction. Samples
were loaded into a quartz cuvette and placed into the FluoroMax-3 spectrofluorometer (Horiba, John Yobin) heated to
43 °C. Aggregation of CS, with and without Hsp31, was measured by light scattering with the excitation and emission set to
360 nm and a slit width of 2 nm. BSA fraction V and hchA
served as negative and positive controls. Measurements were
taken every second for 2,000 s. Data were plotted using
GraphPad Prism version 5.0.
Reducing Agent-induced Aggregation of Insulin (38, 39)—
Briefly, Hsp31 was buffer-exchanged into PBS (pH 7.2). Insulin
was diluted with PBS to 26 M, and 4 or 8 M of Hsp31 was used
in a 500-l reaction. Samples were loaded into a quartz cuvette
and placed into the FluoroMax-3 spectrofluorometer. Aggregation of insulin induced by 20 mM DTT, with and without
Hsp31, was measured by light scattering with the excitation and
emission set to 360 nm and a slit width of 1 nm. Measurements
were taken every second for 2,000 s. Data were plotted using
GraphPad Prism version 5.0.
Spontaneously Fibrillizing Syn Assay—The procedure for
performing the Thioflavin T aggregation assay was described
previously (40). The Syn was prepared by centrifuging the
recombinant protein through a 100 kDa spin filter to remove
preformed oligomers (35). DJ-1 and Hsp31 purified from either
E. coli or Saccharomyces cerevisiae, respectively, were incubated with Syn (17.5 M) for 5 days at 37 °C. Thioflavin T (20
M), a fluorescent dye that emits a signal only when binding to
-sheet-containing protein aggregates, was included in the
reaction to detect the fibrillar state of Syn by a Spectrafluor
Plus microplate reader (Tecan, Uppsala, Sweden) at 440 nm for
the excitation and 490 nm for the emission wavelength.
Dilution Growth Assays
Plasmids (pAG415-GPD-ccdB-DsRed and pAG415-GPDHsp31-DsRed) were transformed into W303 Syn-expressing
strains with or without a genomic copy of the HSP31 gene
knocked out using the PEG/lithium acetate transformation
method. Single colonies of transformants were grown in
SDLeu overnight, and the cells were washed, normalized,
and grown in synthetic complete medium without leucine
(SCLeu)  raffinose (2%) to switch the carbon source. After
incubating in the raffinose medium overnight, the cell number
was normalized, and dilutions were aliquoted on an SDLeu
(suppressed expression) plate and SCLeu with 2% raffinose
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41

DASBMB

and 2% galactose (induced expression) with 5-fold serial dilutions. The plates were incubated at 30 °C for 3 days.
Fluorescence Imaging of Syn Localization
pESC-Leu myc-Hsp31 and control empty vector were transformed into two copies of Syn-expressing strain. The Syn
expression was induced by growing cells in synthetic minimum
medium plus 2% raffinose and 2% galactose for 8 h. The live
cells were visualized using a Nikon TE2000-U inverted fluorescence microscope with Nikon Plan apochromat 60 (numerical aperture 1.4) oil immersion objective and YFP filters plus
300 magnification. In order to differentiate the localization of
protein, 50 individual cells were randomly counted in multiple regions of interest for each set of experiments. The ratio of
membrane to cytoplasmic localization of Syn fluorescent
fusion protein was presented as the mean from three independent sets of experiments.
MGO Addition and Microscopy

Syn-expressing strains with or without the HSP31 gene
deleted were grown in liquid yeast extract/peptone dextrose
medium and transferred into medium containing 2% galactose
and MGO (0.5–2 mM) for 6 and 12 h. Cells were washed and
subjected to confocal microscopy to observe Syn foci formation. The presence of MGO inhibited the growth of cells for the
initial 12 h and resulted in an equal growth rate between strains
regardless of the HSP31 gene deletion. Strains could not be
grown in the presence of high concentrations of MGO (20 mM),
so Syn was induced for 10 h, and then MGO was added and
incubated for another 2 h before confocal microscopy analysis.
Assessment of Intracellular ROS
Cells were harvested after the induction of Syn expression
for 12 h, and 5  106 cells were prepared for staining with
dihydroethidium. Cells were suspended in 250 l of 2.5 g/ml
dihydroethidium in PBS and incubated in the dark for 10 min.
Cells were washed in the PBS and were subjected to fluorescence microscopy (excitation at 485 nm and emission at 520
nm) and flow cytometry with the FL-2 channel. FlowJo software
was used to calculate median fluorescence intensity.
Prion Expression Experiments
W303 wild type strain was co-transformed with pAG424GAL-PrD-Sup35-EYFP and pAG415-GPD-HSP31-DsRed. Single transformations were also performed using the same constructs and their corresponding control vector. Cells were
grown at 30 °C in appropriate medium overnight (SDTrp
for pAG424, SDLeu for pAG415, and SDTrpLeu for cotransformants), and protein expression was induced for 24 h in
SC 2% raffinose and 2% galactose-containing medium at 30 °C.
After induction, cells were subjected to fluorescence microscopy using a Nikon A1 confocal microscope with a Nikon Plan
apochromat 60 (numerical aperture 1.4) oil immersion objective to acquire fluorescence and differential interference contrast images and were analyzed using ImageJ. Cultures identical
to those used in microscopy were used to prepare samples for
flow cytometry, and cells were washed and resuspended in PBS
at a density of 10  106 cells/ml. Cells were filtered and anaJOURNAL OF BIOLOGICAL CHEMISTRY
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lyzed for EYFP fluorescence intensity using a flow cytometer
with the FL-1 channel. A total of 10,000 events were acquired
for each sample, and data were analyzed using FlowJo software
to calculate median fluorescence intensity after three biological
replicates.
Glutathione-independent Glyoxalase Biochemical Assay
Purified recombinant Hsp31 and Hsp31 C138D with the
GST tag removed were used to assay methylglyoxalase activities. The reaction was initiated by adding the specified concentration of proteins (1 M Hsp31 and 5 M Hsp31C138D) in
reaction buffer (100 mM HEPES, pH 7.5, 50 mM KCl, 2 mM
DTT) to a 6 mM initial concentration of MGO (Sigma; 40%
solution), followed by incubation at 30 °C. The assay was performed by removing 50-l aliquots of the reaction at fixed time
points (15, 30, 45, and 120 s) after the addition of protein. The
amount of D-lactic acid produced by Hsp31 as a result of MGO
consumption was measured. The initial rate obtained was
divided by the amount of protein in the reaction mixture to
calculate the specific activity. Samples were also subjected to
gas chromatography-mass spectroscopy analysis (Agilent
5975C MSD) to identify the presence of D-lactic acid. Samples
were derivatized with N,O-bis(trimethylsilyl) trifluoroacetamide) and trimethylchlorosilane and heated to 50 ºC for 10
min and run in the electron impact mode with scanning from
42 to 400 atomic mass units. A lactic acid standard displayed a
peak at 6.09 min identical to the peak detected in the Hsp31treated sample, whereas Hsp31C138D did not display this peak.
The spectral scan was visualized and displayed using the
OpenChrom software (41). To obtain the enzymatic parameters, the reaction was initiated as described above by adding 1
M Hsp31 or 5 M Hsp31C138D protein into reaction buffer,
and reactions were stopped after 1 min by heating at 85 °C for
30 s. A range of MGO substrate from 50 M to 2 mM and the
EnzyFluo D-lactate assay kit (Bioassay Systems) were used to
determine the amount of D-lactic acid produced in each reaction. Each rate was determined in triplicate, and mean values
were plotted to obtain enzymatic parameters (Vmax and Km) by
fitting to a Michaelis-Menten model using GraphPad Prism.
Semidenaturing Detergent-Agarose Gel Electrophoresis
(SDD-AGE)
W303 cells harboring pAG424-GAL-cPrDSup35-EYFP and
pAG415-GPD-HSP31-DsRed plasmids were used, and aggregates were produced by inducing for 24 h in SC 2% raffinose 
2% galactose medium. Prion aggregates were analyzed using
SDD-AGE (42). Briefly, to prepare lysates, cells were harvested
by centrifugation at 3,000  g for 2 min and resuspended in
spheroplast solution (1.2 M D-sorbitol, 0.5 mM MgCl2, 20 mM
Tris (pH 7.5), 50 mM -mercaptoethanol, and 0.5 mg/ml
Zymolyase) and incubated at 30 °C for 30 min with shaking.
After spheroplast formation, the samples were centrifuged at
800 rpm for 5 min at room temperature, and supernatant was
removed. The pelleted spheroplasts were resuspended into 100
l of lysis buffer (100 mM Tris, pH 7.5, 50 mM NaCl, 10 mM
-mercaptoethanol, and protease inhibitor) and vortexed at
high speed for 2 min. The lysates were collected and mixed with
4 sample buffer (2 TAE, 20% glycerol, 4% SDS, 0.01% bro-
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mphenol blue). The samples were incubated at room temperature for 15 min and loaded onto a 1.8% agarose gel containing
1 TAE and 0.1% SDS and run at 50 V, followed by transfer
onto nitrocellulose membrane using the capillary transfer
method. The nitrocellulose membrane was subjected to Western blot analysis using anti-GFP antibody (Roche Applied Science). A strain harboring p2HG-Hsp104 plasmid was included
as a positive control.

Results
Hsp31 Has Chaperone Activity—The S. cerevisiae open reading frame (YDR533C) has been assigned the name HSP31; however, direct functional studies demonstrating chaperone activity have not been conducted on this protein to support its
designation within the HSP family. Hsp31, human DJ-1, and
hchA are members of the ThiJ/DJ-1 superfamily based on similarity in structure, so we directly compared the in vitro chaperone activity between these proteins. The influence of Hsp31
on the aggregation of substrate proteins was measured using
three different model substrates: CS, insulin, and Syn. CS has
been used as a classical substrate for in vitro chaperone assays,
and both DJ-1 and hchA have demonstrated an ability to suppress CS aggregation (9, 43). To assess the chaperone activity of
Hsp31, we purified the protein from yeast using the BG1805
plasmid-based system from the yeast movable ORF (MORF)
collection (33). The C terminus of the protein retains a 4.8-kDa
tag, as confirmed by mass spectrometry, and includes a His6
and HA tag (see the amino acid sequence under “Experimental
Procedures”). We also expressed Hsp31 with a GST tag fused to
its N terminus using the pGEX-6p1 plasmid in E. coli. The tag
was removed by 3C protease, and only 3 amino acids (GPL)
were retained on the recombinant Hsp31 protein, which was
confirmed by mass spectrometry (data not shown). We determined that the purified proteins were folded correctly because
they behaved as homodimers based on gel filtration chromatography (data not shown) and by analytical ultracentrifugation
with a sedimentation coefficient of 3.7 S (Fig. 1A). The Hsp31MORF, purified from yeast, can completely suppress the heatinduced aggregation of CS when present at a 1:1 molar ratio
(Fig. 1B). BSA, which was added at a 6-fold molar excess concentration of CS, had a slight effect on suppressing CS aggregation in agreement with a previous study that reported BSA as
having a mild chaperone effect in the CS aggregation assay (44).
E. coli hchA suppressed CS aggregation in a dose-dependent
manner, but the high concentration of 0.6 M did not approach
the considerably more efficient suppression of CS aggregation
by Hsp31-MORF (Fig. 1B). In addition, recombinant yeast
Hsp31 purified from E. coli did not have activity at a 1:1 molar
ratio and was needed at high molar ratios similar to hchA (data
not shown) (Fig. 1B). In conclusion, Hsp31 purified from yeast
can suppress CS aggregation at a 1:1 molar ratio, whereas hchA
is needed at a 6:1 molar ratio to generate an appreciable suppression of aggregation. These results are consistent with previous studies, where high molar ratios of hchA were required in
CS assays (38, 45).
To further characterize the chaperone activity of Hsp31,
additional protein substrates were studied. Hsp31-MORF suppressed insulin aggregation induced by reducing agent, when
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FIGURE 1. Hsp31 inhibits in vitro protein aggregation of a variety of substrates. A, the predominant form of Hsp31 is a homodimer in solution. Hsp31 was
purified from the pGEX E. coli expression plasmid, and the GST tag was proteolytically removed. Sedimentation velocity was performed, and the c(s) distribution plot demonstrated that the majority species at 3.7 S is a dimeric protein. B, Hsp31 inhibited CS aggregation. CS at 0.1 M reached a maximum aggregation
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(2 M (Œ), 1 M ( ), and 0.5 M ()). DJ-1 (5 M) (f) was used as the positive control in the assay. These data are representative of more than five independent
experiments with all experiments demonstrating similar trends.

using a 3– 6-fold molar excess of insulin (Fig. 1C), further establishing its chaperone activity in another commonly used chaperone assay. The mechanism of Syn aggregation is unclear,
and DJ-1 has been reported to decrease Syn aggregates or
cytoplasmic foci in vitro and in vivo (9, 14, 46, 47). Hsp31 completely suppressed Syn fibrillization despite the presence of an
8-fold molar excess of Syn and maintained chaperone activity
when Syn was present at a 35:1 molar ratio (Fig. 1D). In agreement with this result, we observed that DJ-1 suppressed Syn
fibrillization although not to the same extent as Hsp31. The
difference may be due to the oxidation state of DJ-1, which has
been shown to affect its activity (46). Taken together, these
results demonstrate that Hsp31 has the ability to act as a chaperone in preventing several types of protein aggregation at substoichiometric concentrations.
Hsp31 Protects against Syn Toxicity and Reduces Syn Foci
Formation and ROS Levels—Outeiro and Lindquist (23) demonstrated that two genomic copies of GAL-Syn in yeast
decreased cellular fitness, which was correlated with Syn cellular aggregates (46). DJ-1 has been reported to alleviate protein
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41
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aggregation (9, 46), and Syn has been implicated as a factor in
the progression of PD (48 –50). To determine the chaperone
effect of Hsp31 with its anti-aggregation activity and effect on
cellular fitness, we tested the rescue of yeast cells from Synmediated toxicity in dilution growth assays. Overexpression of
one copy of the Syn gene from the GAL (galactose) promoter
had negligible effects on cellular fitness, but GAL-driven overexpression of two Syn gene copies resulted in severe toxicity,
confirming previous findings of dose-dependent toxicity. The
Syn toxicity was markedly alleviated in the presence of constitutive expression of Hsp31 (pGPD-HSP31), as evidenced by the
full rescue of cell viability (Fig. 2A). In addition, we expressed
one copy of GAL-Syn in an hsp31 strain to determine
whether there was a synthetic genetic interaction between
these genes. Dilution growth assays demonstrated that expression of a single copy of Syn or knocking-out HSP31 alone was
phenotypically similar to the wild-type strain with respect to
viability. However, cellular fitness was significantly reduced
when expressing a single copy of Syn in the hsp31 strain (Fig.
2B). The synthetic lethal interaction of Syn and deleted HSP31
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using this approach provided further evidence that Hsp31 is a
molecular chaperone with the ability to protect cells from
Syn-mediated toxicity.
Previous studies demonstrated that the subcellular localization of Syn changed from the plasma membrane to cytoplasmic foci with increased expression of Syn in yeast cells (23).
Using this relocalization property, we examined the effect of
pGAL HSP31 overexpression in altering the distinctive subcellular localization profile of 2xGAL-Syn. The same strains used
in the dilution growth assay were used to monitor the effect of
Hsp31 expression on Syn localization. We quantified the
number of cells with specific localization profiles at 8 h postinduction and observed that 60% of cells exhibited Syn foci
when only expressing Syn, but only 33% of cells co-expressing
Syn and Hsp31 contained foci (Fig. 3, A and B). We observed
that the suppression of Syn foci by pGAL HSP31 was transient
because 24 h after induction, the percentage of cells with foci
increased and was similar to the percentage observed for cells
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expressing Syn alone. This result is consistent with our rescue
experiments, which were only successful when HSP31 was
expressed from the GPD promoter (Fig. 2, A and B) and not
when expressed from the GAL promoter (data not shown).
The expression of Syn has been demonstrated to increase
the level of ROS in yeast (51). The in vivo suppression of Syn
foci by Hsp31 and increased toxicity of one copy Syn in the
hsp31 strain prompted us to investigate the level of ROS in
these different genetic contexts. We found that wild-type yeast
did not have detectable superoxide radicals when treated with
dihydroethidium using microscopy and a fluorescence level of
0.5 arbitrary units by flow cytometry (Fig. 3, C and D). ROS
levels were detectable in a fraction of cells in the hsp31 strain
(6 arbitrary units), indicating that the presence of Hsp31 in the
cell can decrease ROS levels of normal cells not expressing
Syn. The remaining strains had increased ROS levels in the
following order: Syn-YFP strain (23 arbitrary units), SynYFP hsp31 (41 arbitrary units), Syn-YFP Syn-CFP (64 arbitrary units), and Syn-YFP Syn-CFP hsp31 (133 arbitrary
units). The latter three strains with the highest ROS levels
exhibit reduced viability when Syn is expressed and form
increased foci, demonstrating a correlation between these
phenotypes.
Hsp31 Is an Integral Part of the Yeast Cellular Stress
Response—Multiple studies have shown that environmental
stresses, such as oxidative stress and increasing temperature,
increase the expression of Hsp31 (26, 52). A recent study demonstrated increased HSP31 mRNA levels upon treatment with
H2O2, during the diauxic shift growth phase and stationary
phase (22). However, the Hsp31 protein level was not characterized under these conditions. We generated a yeast strain
with a genomically integrated 9myc epitope at the C terminus
of the HSP31 locus to quantify protein expression. We examined Hsp31 protein expression levels during growth in rich
media relative to optical density and demonstrated that Hsp31
expression could be divided into three phases. We found that
Hsp31 expression decreased during log phase and then reached
maximum expression during early stationary phase relative to
the cell density of the culture and remained at approximately
the same level in stationary phase when cell density was saturated after growth for 24 h (Fig. 4A). This distinctive
expression pattern results in the initiation of elevated
expression of Hsp31 corresponding to the diauxic shift, which
occurs between log phase and stationary phase (26). To assess
whether Hsp31 expression increases under other stress conditions, we exposed cells to H2O2 and observed increased
protein expression within 1 h of exposure (Fig. 4B). This
increased expression in response to an ROS-inducing agent has
been observed previously (22, 26).
We also examined the expression profile of Hsp31 to a proteotoxic stress in the form of Syn overexpression, and the
results indicated that increased expression of Syn decreases
cell viability and concomitantly increases the expression of
Hsp31 during log phase compared with a strain not expressing
Syn (Fig. 4, C–E). The characteristic decrease in expression
during log phase, 6 –9 h postinoculation, is not observed when
Syn is expressed. Our data demonstrate that Hsp31 expression is rapidly elevated at the protein level in the event of
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growth stress associated with diauxic shift, oxidative stress, and
proteotoxicity.
Hsp31 Methylglyoxalase Activity Is Not Required for Rescue of
Syn-mediated Toxicity—Recent studies have shown that DJ-1
and Hsp31 are methylglyoxalases that convert MGO into D-lactate in a single step independent of GSH (53, 54). Hsp31, like
other members of the DJ-1 superfamily, possesses the conOCTOBER 9, 2015 • VOLUME 290 • NUMBER 41
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served Glu-Cys-His catalytic triad (18). The first two residues of
this triad are critical for MGO activity of DJ-1 as well as Hsp31
in Schizosaccharomyces pombe (54). We determined the methylglyoxalase activity for recombinant Hsp31 (purified from
E. coli with the GST tag removed to retain 3 amino acids, GPL,
on the C terminus) and a catalytic triad mutant, Hsp31 C138D,
using a commercially available D-lactate assay kit. As expected,
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Hsp31 could convert MGO into D-lactate with a calculated specific activity of 28.4 mol/min/mg enzyme (using a saturating
substrate concentration of MGO at 6 mM). These enzymatic
parameters indicate a more efficient enzyme activity than the
previously reported Hsp31-specific activity of 10.5 D-lactate
mol/min/mg (53). The Hsp31-MORF purified from yeast had
similar enzymatic parameters as the recombinant Hsp31 (data
not shown). Enzymatic parameters were calculated by measuring the time-dependent production of D-lactate with varying
substrate concentrations and fitting to a Michaelis-Menten
kinetics model, resulting in a Vmax of 0.0356 mol of D-lactic
acid/min (S.E. 0.0016), and Km was 247.4 M (S.E. 31.5)
(Fig. 5A). Specific activity for the mutant could not be determined because low levels of D-lactate were produced despite
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using 5 times the amount of protein (detection limit of 0.4
mol/min/mg). The reaction products of these assays were
examined by GC-MS, and a peak identical to the lactic acid
standard (6.09-min elution time) was identified, confirming the
production of lactic acid by Hsp31 (Fig. 5B). Lactic acid was
undetectable by GC-MS analysis in the Hsp31 C138D sample
(data not shown).
We next determined whether methylglyoxalase activity is
required for rescue of Syn toxicity. One copy of Syn-YFP
decreases fitness in the hsp31 strain, but GPD-driven expression of Hsp31 rescues that toxicity. The expression of GPDdriven Hsp31 C138D restored the Syn-expressing strain to full
viability comparable with expression of the wild-type Hsp31
(Fig. 5C). The lack of enzyme activity for this mutant and the
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ability to rescue Syn toxicity indicated that the in vivo mechanism of rescue is not dependent on methylglyoxalase activity.
MGO is a toxic metabolite produced during glycolysis (53–
55) that reacts with proteins to yield toxic advanced glycation
end products (56, 57) and has been associated with increased
Syn cross-linking and formation of intracellular foci formation in neuroblastoma cells (58). We examined whether
increased levels of MGO could increase the Syn foci or toxicity by treating cells with exogenous MGO and found no increased foci in wild-type yeast, indicating that their formation is
probably not influenced by MGO. In addition, the hsp31
strain also did not have increased foci, suggesting that lack of
Hsp31 is not sufficient to increase foci formation due to MGO
treatment (Fig. 6, A and B). We determined that MGO was toxic
to wild-type yeast at 10 and 20 mM MGO, and viability in the
hsp31 strains was similar to wild type, suggesting that Hsp31
is not sufficient for detoxification. The concomitant expression
of Syn (one or two copies) and treatment with MGO did not
have differential effects on viability (Fig. 6C). Consistent with
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41
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these results is that cell lysates of the hsp31 strain had levels of
overall methylglyoxalase activity equivalent with those of wild
type because other yeast methylgloxalase enzymes, Glo1 and
Glo2, are present in yeast and have been shown to detoxify
MGO (59, 60) (data not shown).
Hsp31 and Catalytic Triad Mutants Prevent the Transition
of Syn Monomers to SDS-resistant Oligomeric Species—The
demonstrated chaperone activity of Hsp31 prompted us to
investigate at what stage Hsp31 prevents protein aggregation.
We used the spontaneous in vitro fibrillization of Syn assay as
a method to investigate the different oligomeric species in the
presence of Hsp31. The prolonged incubation of recombinant
monomeric Syn results in fibrillization and precipitation of
the protein. Fractionation of the precipitate versus supernatant
and subsequent electrophoresis on SDS-PAGE allowed the
detection of different oligomeric species that appear to be SDSresistant (Fig. 7A). The Syn higher order oligomers were
reduced in the pellet fraction and nearly non-existent in the
supernatant when Hsp31 wild-type and catalytic triad mutants
JOURNAL OF BIOLOGICAL CHEMISTRY
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were present (Fig. 7B). The greatly reduced presence of soluble
but SDS-resistant oligomers indicates that Hsp31 may interact
with the monomer or an early oligomeric species to prevent
formation of later stage oligomers. The same reactions were
monitored using the ThioT assay, and only a baseline level of
fluorescence was observed in the presence of Hsp31, further
supporting the hypothesis that Hsp31 interacts with an Syn
species that precedes larger oligomers detected by ThioT (Fig.
7C). The ability of mutants to reduce fibrillization is consistent
with our observation that the mutants suppress Syn toxicity in
yeast (Fig. 5C).
Hsp31 Prevents Formation of Large Prion Aggregates—The
demonstration that Hsp31 possesses chaperone activity in a
variety of anti-aggregation assays prompted us to investigate
whether Hsp31 could also modulate the oligomeric state of
yeast prion proteins, such as the Sup35 prion. The aggregation
state of prions in living cells can be monitored by fusion of
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fluorescent protein tags to prion-forming domains (PrD), so we
overexpressed Hsp31 to determine whether it modulated the
aggregation of Sup35 PrD. Consistent with previous findings,
cells overexpressing PrD in the presence of endogenous Sup35
showed characteristic ribbon-like or punctate aggregates,
which were localized around the vacuoles and/or adjacent to
plasma membranes (Fig. 8A). The number of cells co-expressing pGPD-HSP31-DsRed and pGAL-PrD-Sup35-EYFP had
3-fold fewer Sup35 fluorescent aggregates compared with
cells harboring pGAL-PrD-Sup35-EYFP plus vector control,
indicating that Hsp31 can inhibit the formation of microscopically visible Sup35 prion aggregates (Fig. 8, A and B). The
intrinsic fluorescence of Sup35-EYFP appears to increase upon
aggregation, which allowed us to utilize flow cytometry as
an alternative method to quantitatively measure and show
decreased Sup35 aggregation (Fig. 8C). This phenomenon has
not been exploited widely but was noted in at least one previous
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study investigating the aggregation of a huntingtin-GFP fusion
protein (61). Cell cultures co-expressing Sup35 and Hsp31 used
in the microscopy experiments were prepared for flow cytometry and analyzed for EYFP fluorescence intensity. The flow
cytometry results were similar to the microscopy results
because Hsp31-expressing cells consistently exhibited lower
median Sup35-EYFP fluorescence intensity when compared
with cells containing Sup35-EYFP expression plasmid and
empty vector (Fig. 8C). Individual traces depicting the number
of counting events for each yeast strain also show the decrease
in cellular fluorescence intensity when Hsp31 is expressed (data
not shown).
Expression of Hsp31 with the GPD promoter was diffuse and
cytoplasmic and varied in intensity in individual cells across the
total cell population. The cytoplasmic localization profile of
Hsp31 was not altered when PrD-Sup35 was expressed (Fig.
8A). Interestingly, we observed overlapping localization in cells
with Sup35 aggregates and relatively high levels of Hsp31, but
the proteins do not appear to mutually co-localize (Fig. 9A). In
some cells, it was evident that the DsRed signal was decreased in
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41
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the area where there was a Sup35 aggregate, suggesting that
Hsp31 is not incorporated in aggregates (Fig. 9A). The aggregate appears to occlude Hsp31, and the diffuse overlapping
signal observed in some cells is consistent with the presence
of Hsp31 throughout the cytoplasm surrounding the aggregate. We also confirmed that Hsp31 overexpression reduces
the formation of in vivo aggregates based on assessing cell
lysates by SDD-AGE. We found that SDS-resistant Sup35
aggregates were greatly reduced when Hsp31 was overexpressed. The positive control, Hsp104, completely eliminated detectable Sup35 aggregates (Fig. 9B). These results
are consistent with the ability of Hsp31 to inhibit the formation of large protein aggregates.
We also ascertained whether other chaperones are induced
upon overexpression of Hsp31. We demonstrated that Hsp70
and Hsp104 expression are not altered, and hence elevated
expression of these chaperones is not responsible for the
observed suppression of prion aggregates (Fig. 9C). This is in
agreement with our in vitro aggregation studies establishing
that purified and recombinant Hsp31 protein is solely sufficient
JOURNAL OF BIOLOGICAL CHEMISTRY

24827

Hsp31 Is a Stress Response Chaperone
A

DIC

+

0..

"-

>LU
c:i

c::

-0 0..

~ >=

Cl LU

--'- c:i
~

M

0. 0..

:c +
+
-0

"

~

~

9 8">
u

M

~

;:r:

B

C
15

*

***

t

IO

·u

<8
£
j

,r,

"il

5

~

u

15
0

::i

$
;,.

-~ IO

"'

"
.§

"u
"~"'

5

~

0

::,

.;::
0

0
pGPD HSP3I -DsRed

pGPD

pGAL

cPrD-EYFP cPrD- EYFP
+ HSP3/-

cPrD-EYFP
+ pGPD

DsRed

FIGURE 8. Fluorescence microscopy demonstrating Hsp31 suppression of Sup35 aggregation. A, PrD-Sup35 produced ribbon-like and punctate aggregates that are decreased when Hsp31 is overexpressed. PrD-Sup35-EYFP was overexpressed for 48 h at 30 °C in control W303 cells or W303 cells expressing
elevated levels of Hsp31. Hsp31 was diffuse in the cytoplasm and decreased the presence of Sup35 aggregates. The diffuse cytoplasmic localization of Hsp31
did not appear to be altered as a result of Sup35 expression. B, quantitation of cells with one or more Sup35-EYFP foci. A smaller proportion of cells with Sup35
aggregates was evident in Hsp31-overexpressing cells compared with vector control (pGPD). Values represent mean  S.E. (n 3). ***, two-tailed Student’s t
test; p  0.001. C, quantitation of Sup35-EYFP fluorescence suppression by Hsp31 using flow cytometry. Hsp31 overexpression lowers the median fluorescence
intensity (FI; arbitrary units (A.U.)) of Sup35 compared with empty vector control. *, two-tailed Student’s t test; p  0.05). Error bars, S.E.; n 3 biological
replicates. DIC, differential interference contrast.

to prevent protein aggregation, although we cannot exclude the
possibility that Hsp31 could collaborate with other chaperones
to prevent prion aggregation in the cell.
Hsp31 Rescue of Syn-mediated Toxicity Is Independent
of the Autophagy Pathway—Recently, in several studies,
autophagy has been identified as one of the main mechanisms
to clear and recycle misfolded proteins and aggregates in the
cytosol (62, 63). In addition to the ubiquitin proteasome system,
autophagy is a major cellular function involved in clearance of
misfolded and aggregated proteins, including Syn aggregates
(62). Deletion of autophagy genes, such as ATG5 or ATG7,
leads to neurodegenerative disease in mice (64, 65). In yeast,
deletion of the ATG1 gene reduced the clearance of Syn aggregates (66). Deletion of HSP31 was also demonstrated to impair
autophagy under carbon starvation conditions (22). These
studies raise the possibility that Hsp31 could be promoting
autophagy of aggregated protein. In order to exclude the possibility that the Hsp31 rescue effect on Syn toxicity depends on
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autophagy, we deleted the ATG8 gene in the Syn strains and
assessed the synthetic lethal effects of Syn expression in these
strains. As expected, expression of Syn in the atg8 strain
resulted in decreased viability compared with the wild-type
strain. The atg8 hsp31 strain had viability similar to that of
the atg8 strain when Syn was expressed (Fig. 10A). These
results confirm that autophagy is a protective mechanism
against Syn toxicity. The lack of synthetic lethal defect
between ATG8 and HSP31 with and without Syn expression is
consistent with genes that are in the same pathway and hence
do not buffer each other. Expression of Hsp31 and the C138D
mutant in the autophagy strains, atg8 Syn or atg8 hsp31
Syn, increased viability in rich YEP media compared with vector controls (Fig. 10B). We found that the rescue effect in synthetic media was not easily observed because expression of
Syn was not toxic in the atg8 strain background, but it was
toxic in the hsp31, indicating that media conditions are an
important factor in this complex relationship (Fig. 10B, mid-
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dle). These results demonstrate that Hsp31 can rescue Syn
toxicity in autophagy-deficient cells.

Discussion
The roles of chaperones and proteases in maintaining integrity and activity of folded, partially folded, and misfolded proteins are well established. Members of the DJ-1/ThiJ/PfpI
superfamily exist in prokaryotes and eukaryotes, and structural
and biochemical analyses have established that they have multiple activities, including chaperone, protease, and enzymatic
functions. Because of the multiple activities associated with this
superfamily, we sought to characterize the chaperone activity of
Hsp31 and delineate its contribution in protecting against cellular stress.
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41

§ ASBMB

The crystal structure of yeast Hsp31 has been solved, and
structural evidence shows that Hsp31 and hchA share high similarity, in terms of the position of a hydrophobic patch and a
catalytic triad. Yeast Hsp31, E. coli hchA, and human DJ-1 are
in the same DJ-1/PfpI/ThiJ superfamily, and the literature suggests that both DJ-1 and hchA have chaperone-like effects
against protein aggregation. Despite these similarities, the
structures differ in important details, and it could have been
argued that Hsp31 might not possess chaperone activity based
on the absence of 45 amino acids present in hchA and the distinct dimerization. We investigated whether the chaperonelike activities are conserved in Hsp31 and found that the protein
showed broad chaperone activity on three different substrate
proteins, with aggregation induced by different mechanisms.
JOURNAL OF BIOLOGICAL CHEMISTRY
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CS aggregation is triggered by elevated temperature, and we
demonstrated that Hsp31 suppresses CS aggregation 6-fold
more efficiently then hchA and DJ-1. Hsp31 also suppresses
insulin aggregation, demonstrating that Hsp31 can maintain
chaperone activity in a reducing environment in contrast to the
redox-dependent DJ-1, which does not have activity in this
assay.
Hsp31 also exhibited considerable activity in an in vitro Syn
fibrillization assay and completely suppressed fibrillization at a
molar ratio of 8.75:1 (Syn/Hsp31) and maintained considerable activity at a ratio of 35:1. DJ-1 also had activity at substoichiometric levels but required higher molar ratios compared
with Hsp31. We consistently observed that the Hsp31-MORF
purified from yeast was more active than recombinant Hsp31,
DJ-1, or hchA (Fig. 1, B and D). This could be due to the fusion
tag type or fusion orientation affecting protein activity, which
has been noted previously for hchA (17, 18). Further studies are
needed to delineate the source of these activity differences,
including the possibility that it is related to the purification
procedure, oxidation state of the protein, oligomeric state, or
post-translational modifications. The broad range of substrates
and substoichiometric activity all indicate that Hsp31 is a chap-
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erone with robust activity compared with other members of
this superfamily.
Despite the fact that its cellular function is incompletely
understood, Syn is known to aggregate and form inclusions.
These protein inclusions are precursors of Lewy bodies, the
pathological hallmark of PD. Elucidating mechanisms of Syn
aggregation is important to understand PD pathogenesis, and
the heterologous expression of Syn in yeast established a useful platform to investigate Syn biology (9). We extended the
Syn yeast model by demonstrating the modulation of Syn
toxicity and subcellular localization by Hsp31. Expression of
2xGAL-Syn is toxic to yeast cells, and constitutive expression
of Hsp31 from the GPD promoter rescued cells from Synmediated toxicity (Fig. 2). In addition, expression of one copy of
GAL-Syn is not toxic to wild-type cells but is toxic in the
hsp31 strain. Taken together, it appears that the chaperone
effect of Hsp31 is necessary to maintain cellular fitness upon
Syn expression.
Hsp31 also altered the subcellular localization profile of
Syn. Expression of 2xGAL-Syn results in cytosolic accumulations (foci), whereas the expression of one copy of GAL-Syn
results in primarily plasma membrane localization. The in vivo
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cytoplasmic foci are associated with vesicular membranes (39),
and analysis of cellular lysates indicates the presence of higher
order oligomeric forms of Syn, although the nature of this
aggregation is unclear (23, 67). Expression of GAL-HSP31
results in more than 2-fold suppression of foci and increases the
localization of Syn to the plasma membrane (Fig. 3A). This
effect was transiently observed at 8 h postinduction, but a high
rate of puncta formation returned after 24 h, possibly because
Hsp31 expression was induced at the same time as Syn. This is
consistent with the result where GAL-HSP31 does not rescue
the synthetic lethal effect of Syn expression in the hsp31
strain, whereas the constitutive GPD-HSP31 rescues hsp31.
These results indicate that a higher threshold level of Hsp31 is
needed in the cell prior to Syn induction to prevent toxicity.
The exact temporal relationship between Hsp31 expression
and Syn foci suppression could provide insight into the aggregation state of Syn species targeted by Hsp31.
Several orthologous experiments suggest that Hsp31 interacts early in the misfolding process and prevents the formation
of larger oligomeric species. The addition of Hsp31 to Syn
monomers in a fibrillization assay resulted in a baseline level of
ThioT fluorescence signal, indicating that the formation of
larger oligomeric species was prevented (Fig. 1D). Analysis
of the SDS-resistant oligomeric species by SDS-PAGE demonstrated that the presence of Hsp31 prevented the formation of
higher order oligomeric Syn species (Fig. 7A). Our prion
aggregation studies indicate that Hsp31 inhibits prion assembly
before the formation of subcellular visible GFP-tagged PrD
aggregates and those detected by SDD-AGE (Fig. 9B). Furthermore, the Sup35 aggregates occlude Hsp31, indicating that the
anti-aggregation activity of Hsp31 commences prior to the formation of the visible aggregate and probably does not act to
remove or disassemble any preformed aggregate (Fig. 9A). This
is in contrast to large chaperones, Hsp104, Ssa1/2, Sis1, and
Sse1, which mutually colocalize with prion aggregates (68). A
previous study has demonstrated that small HSPs can inhibit
the formation of Sup35 aggregates and found that Hsp26 and
Hsp42 inhibit rare transient oligomers at distinctly different
steps in the prion formation process (69). Further studies will be
required to determine whether Hsp31 inhibits protein misfolding with a similar or distinct mechanism as Hsp26 or Hsp42.
Overall, we demonstrate that Hsp31 can inhibit oligomerization or aggregation of many different proteins by intervening
early in the process.
The role of Hsp31 in protecting cells from Syn-mediated
toxicity led us to investigate the expression of Hsp31 in
response to proteotoxic stress and other types of stress. The
expression pattern of Hsp31 in a genomically tagged strain
decreased during log phase growth and increased at the diauxic
shift and at saturation (Fig. 4). The increased expression of
Hsp31 at the diauxic shift and in stationary phase could possibly
be due to the stress of decreased nutrients or accumulation of
metabolites associated with these growth phases and is part of a
global transcriptional response program (70). An increase in
Hsp31 expression in response to ROS has been observed previously (71), and we confirmed that our tagged strain behaved in
a similar manner by demonstrating an increase in expression
upon exposure to H2O2 (Fig. 4B). This ROS response has been
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41
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implicated to be dependent on the Yap1 stress response transcription factor, and a shortened Hsp31 promoter (313 bp
relative to the ATG), which removes the Yap1 binding site
(363 and 353 bp relative to the ATG), has decreased Hsp31
expression in response to oxidative stress (72). However, we
note that the shortened promoter also removes an additional
stress response element (a CCCCT site at 379 to 383 from
the ATG) in proximity to the Yap1 binding site. Stress response
elements have been demonstrated to be the binding site for
Msn2/4, and numerous stress-related yeast genes have been
documented to be transcriptionally activated by these transcription factors (26), including genes up-regulated after the
diauxic shift in stationary phase cells (26). Hsp31 appears to be
part of the global transcriptional stress response by Yap1 and
Msn2/4 or other stress-related transcription factors, such as
Hsf1 or Gis1.
Finally, we also examined the response of Hsp31 expression
during Syn-initiated proteotoxic stress and observed an
increased expression in cells in log phase. We measured an
increase in superoxide levels upon Syn expression consistent
with a previous report that indicated that Syn expression is
associated with caspase-mediated ROS generation (73) (Fig.
3D). Deletion of HSP31 also leads to increased superoxide levels
with or without Syn expression. These results establish that
Hsp31 has a role in response to ROS, and its expression is
induced in response to several types of stress.
We demonstrated the robust chaperone activity of Hsp31,
but the in vivo rescue effects could have been mediated by the
Hsp31 methylglyoxalase activity or interaction with other biological pathways, such as the metabolic or autophagy pathway.
We confirmed that Hsp31 does have methylglyoxalase activity
and demonstrated that mutation of the catalytic triad residue,
C138D, results in greatly reduced methylglyoxalase activity
(Fig. 5, A and B). However, this mutation did not inactivate the
chaperone activity in the Syn fibrillization assay (Fig. 7C), and
expression of GPD-HSP31 C138D rescued cells from Syn-mediated toxicity (Fig. 5C). Furthermore, we showed that that
exogenous MGO did not differentially affect viability, suggesting that Hsp31 does not rescue by reducing accumulation of
this toxic metabolite in Syn-expressing cells (Fig. 6).
We also demonstrated that the autophagy pathway is an
important mediator in the Syn toxicity because deletion of
ATG8 resulted in synthetic lethal interaction with Syn expression (Fig. 10A). This is consistent with atg1 or atg7 strains
having synthetic lethal interactions with Syn expression and
having defects in clearing Syn foci (74). However, we show
that the hsp31 atg8 strain does not have increased Synmediated toxicity when compared with atg8, consistent with
these genes occurring within the same synthetic lethal pathway.
A recent result indicates that hsp31 strains are defective in
autophagy (51), so the addition deletion of an autophagy gene
should not increase toxicity. Interestingly, overexpression of
Hsp31 in these autophagy-deficient strains can rescue cells
from Syn toxicity, indicating that the autophagy pathway is
not essential for chaperone rescue (Fig. 10B). Autophagy may
be beneficial for controlling Syn toxicity, but it appears that
chaperone activity of Hsp31 is also important. These experiments also are the first to delineate that enzymatic methylgJOURNAL OF BIOLOGICAL CHEMISTRY

24831

Hsp31 Is a Stress Response Chaperone
lyoxalase activity of Hsp31 is not essential to rescue Syn
toxicity.
Our results suggest that Hsp31 functions as a cytoplasmic
chaperone against a variety of misfolded proteins. Recent studies have demonstrated the facility of yeast to investigate pathogenic mechanisms underlying Syn toxicity, including the
identification of novel biological pathways that impinge on
Syn biology and small molecule modulators of Syn toxicity
(66, 69). In addition, the action of Hsp31 on Syn may provide
insight into the mode of toxicity of Syn because recent evidence suggests that the Syn toxic species is smaller than the
visible aggregate (66). It should be noted that the prion expression studies done in this study were not completed with [PSI]
strains, but further studies using such strains would be of interest to determine the effect of Hsp31 on prion initiation and
propagation.
We have established a framework that extends the yeast
model for investigating mechanisms of Syn toxicity in the
context of the DJ-1/ThiJ/PfpI superfamily in yeast. Extension of
this work will assist in elucidation of the chaperone-like mechanisms of Hsp31, and a comparison with DJ-1 may provide
evolutionary insights into the activities of the DJ-1/PfpI/ThiJ
superfamily. Our model may also be used to further delineate
the nature of oligomeric species in the pathogenesis of PD
and possibly what species of Syn should be targeted
therapeutically.
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Rosado-Ramos, R., Betzer, C., Straatman, K. R., Jensen, P. H., Giorgini, F.,
and Outeiro, T. F. (2014) DJ-1 interactions with -synuclein attenuate
aggregation and cellular toxicity in models of Parkinson’s disease. Cell
Death Dis. 5, e1350
22. Miller-Fleming, L., Antas, P., Pais, T. F., Smalley, J. L., Giorgini, F., and
Outeiro, T. F. (2014) Yeast DJ-1 superfamily members are required for
diauxic-shift reprogramming and cell survival in stationary phase. Proc.
Natl. Acad. Sci. U.S.A. 111, 7012–7017
23. Outeiro, T. F., and Lindquist, S. (2003) Yeast cells provide insight into
-synuclein biology and pathobiology. Science 302, 1772–1775
24. Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L., and
Muchowski, P. J. (2003) Yeast genes that enhance the toxicity of a mutant
huntingtin fragment or -synuclein. Science 302, 1769 –1772
25. Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar,
B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., Cao, S., Caldwell, K. A.,
Caldwell, G. A., Marsischky, G., Kolodner, R. D., Labaer, J., Rochet, J. C.,
Bonini, N. M., and Lindquist, S. (2006) -Synuclein blocks ER-Golgi traffic
and Rab1 rescues neuron loss in Parkinson’s models. Science 313,
324 –328
26. Skoneczna, A., Miciałkiewicz, A., and Skoneczny, M. (2007) Saccharomyces cerevisiae Hsp31p, a stress response protein conferring protection
against reactive oxygen species. Free Radic. Biol. Med. 42, 1409 –1420

§ASBMB

VOLUME 290 • NUMBER 41 • OCTOBER 9, 2015

Hsp31 Is a Stress Response Chaperone
27. Kim, I. S., Sohn, H. Y., and Jin, I. (2011) Adaptive stress response to menadione-induced oxidative stress in Saccharomyces cerevisiae KNU5377. J.
Microbiol. 49, 816 – 823
28. Takanishi, C. L., and Wood, M. J. (2011) A genetically encoded probe for
the identification of proteins that form sulfenic acid in response to H2O2
in Saccharomyces cerevisiae. J. Proteome Res. 10, 2715–2724
29. de Melo, H. F., Bonini, B. M., Thevelein, J., Simões, D. A., and Morais,
M. A., Jr. (2010) Physiological and molecular analysis of the stress response of Saccharomyces cerevisiae imposed by strong inorganic acid with
implication to industrial fermentations. J. Appl. Microbiol. 109, 116 –127
30. Amberg, D., Burke, D., and Strathern, J. (2005) Methods in Yeast Genetics:
A Cold Spring Harbor Laboratory Course Manual, 2005 Ed., Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, NY
31. Janke, C., Magiera, M. M., Rathfelder, N., Taxis, C., Reber, S., Maekawa,
H., Moreno-Borchart, A., Doenges, G., Schwob, E., Schiebel, E., and Knop,
M. (2004) A versatile toolbox for PCR-based tagging of yeast genes: new
fluorescent proteins, more markers and promoter substitution cassettes.
Yeast 21, 947–962
32. Alberti, S., Gitler, A. D., and Lindquist, S. (2007) A suite of Gateway
cloning vectors for high-throughput genetic analysis in Saccharomyces
cerevisiae. Yeast 24, 913–919
33. Gelperin, D. M., White, M. A., Wilkinson, M. L., Kon, Y., Kung, L. A.,
Wise, K. J., Lopez-Hoyo, N., Jiang, L., Piccirillo, S., Yu, H., Gerstein, M.,
Dumont, M. E., Phizicky, E. M., Snyder, M., and Grayhack, E. J. (2005)
Biochemical and genetic analysis of the yeast proteome with a movable
ORF collection. Genes Dev. 19, 2816 –2826
34. Conway, K. A., Harper, J. D., and Lansbury, P. T., Jr. (2000) Fibrils formed
in vitro from -synuclein and two mutant forms linked to Parkinson’s
disease are typical amyloid. Biochemistry 39, 2552–2563
35. Rochet, J. C., Conway, K. A., and Lansbury, P. T., Jr. (2000) Inhibition of
fibrillization and accumulation of prefibrillar oligomers in mixtures of
human and mouse -synuclein. Biochemistry 39, 10619 –10626
36. Krasnoslobodtsev, A. V., Peng, J., Asiago, J. M., Hindupur, J., Rochet, J. C.,
and Lyubchenko, Y. L. (2012) Effect of spermidine on misfolding and
interactions of -synuclein. PLoS One 7, e38099
37. Brown, P. H., and Schuck, P. (2006) Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys. J. 90, 4651– 4661
38. Sastry, M. S., Korotkov, K., Brodsky, Y., and Baneyx, F. (2002) Hsp31, the
Escherichia coli yedU gene product, is a molecular chaperone whose activity is inhibited by ATP at high temperatures. J. Biol. Chem. 277,
46026 – 46034
39. Sastry, M. S., Zhou, W., and Baneyx, F. (2009) Integrity of N- and C-termini is important for E. coli Hsp31 chaperone activity. Protein Sci. 18,
1439 –1447
40. Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T. M., and Subramaniam, V. (2002) Dependence of -synuclein aggregate morphology on
solution conditions. J. Mol. Biol. 322, 383–393
41. Wenig, P., and Odermatt, J. (2010) OpenChrom: a cross-platform open
source software for the mass spectrometric analysis of chromatographic
data. BMC Bioinformatics 11, 405
42. Halfmann, R., and Lindquist, S. (2008) Screening for amyloid aggregation
by semi-denaturing detergent-agarose gel electrophoresis. J. Vis. Exp. 17,
e838
43. Malki, A., Kern, R., Abdallah, J., and Richarme, G. (2003) Characterization
of the Escherichia coli YedU protein as a molecular chaperone. Biochem.
Biophys. Res. Commun. 301, 430 – 436
44. Marini, I., Moschini, R., Del Corso, A., and Mura, U. (2005) Chaperonelike features of bovine serum albumin: a comparison with -crystallin. Cell
Mol. Life Sci. 62, 3092–3099
45. Choi, D., Ryu, K. S., and Park, C. (2013) Structural alteration of Escherichia
coli Hsp31 by thermal unfolding increases chaperone activity. Biochim.
Biophys. Acta 1834, 621– 628
46. Zhou, W., Zhu, M., Wilson, M. A., Petsko, G. A., and Fink, A. L. (2006) The
oxidation state of DJ-1 regulates its chaperone activity toward -synuclein. J. Mol. Biol. 356, 1036 –1048
47. Zhou, W., and Freed, C. R. (2005) DJ-1 up-regulates glutathione synthesis
during oxidative stress and inhibits A53T -synuclein toxicity. J. Biol.

OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41

DASBMB

Chem. 280, 43150 – 43158
48. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., and Björklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of -synuclein in the nigrostriatal system. J. Neurosci. 22, 2780 –2791
49. Ko, L. W., Ko, H. H., Lin, W. L., Kulathingal, J. G., and Yen, S. H. (2008)
Aggregates assembled from overexpression of wild-type -synuclein are
not toxic to human neuronal cells. J. Neuropathol. Exp. Neurol. 67,
1084 –1096
50. Lee, H. J., and Lee, S. J. (2002) Characterization of cytoplasmic -synuclein
aggregates: fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48976 – 48983
51. Flower, T. R., Chesnokova, L. S., Froelich, C. A., Dixon, C., and Witt, S. N.
(2005) Heat shock prevents -synuclein-induced apoptosis in a yeast
model of Parkinson’s disease. J. Mol. Biol. 351, 1081–1100
52. Miura, T., Minegishi, H., Usami, R., and Abe, F. (2006) Systematic analysis
of HSP gene expression and effects on cell growth and survival at high
hydrostatic pressure in Saccharomyces cerevisiae. Extremophiles 10,
279 –284
53. Hasim, S., Hussin, N. A., Alomar, F., Bidasee, K. R., Nickerson, K. W., and
Wilson, M. A. (2014) A glutathione-independent glyoxalase of the DJ-1
superfamily plays an important role in managing metabolically generated
methylglyoxal in Candida albicans. J. Biol. Chem. 289, 1662–1674
54. Zhao, Q., Su, Y., Wang, Z., Chen, C., Wu, T., and Huang, Y. (2014) Identification of glutathione (GSH)-independent glyoxalase III from Schizosaccharomyces pombe. BMC Evol. Biol. 14, 86
55. Lee, J. Y., Song, J., Kwon, K., Jang, S., Kim, C., Baek, K., Kim, J., and Park, C.
(2012) Human DJ-1 and its homologs are novel glyoxalases. Hum. Mol.
Genet. 21, 3215–3225
56. Angeloni, C., Zambonin, L., and Hrelia, S. (2014) Role of methylglyoxal in
Alzheimer’s disease. Biomed. Res. Int. 2014, 238485
57. Vistoli, G., De Maddis, D., Cipak, A., Zarkovic, N., Carini, M., and Aldini,
G. (2013) Advanced glycoxidation and lipoxidation end products (AGEs
and ALEs): an overview of their mechanisms of formation. Free. Radic.
Res. 47, 3–27
58. Shaikh, S., and Nicholson, L. F. (2008) Advanced glycation end products
induce in vitro cross-linking of -synuclein and accelerate the process of
intracellular inclusion body formation. J. Neurosci. Res. 86, 2071–2082
59. Bito, A., Haider, M., Hadler, I., and Breitenbach, M. (1997) Identification
and phenotypic analysis of two glyoxalase II encoding genes from Saccharomyces cerevisiae, GLO2 and GLO4, and intracellular localization of the
corresponding proteins. J. Biol. Chem. 272, 21509 –21519
60. Inoue, Y., and Kimura, A. (1996) Identification of the structural gene
for glyoxalase I from Saccharomyces cerevisiae. J. Biol. Chem. 271,
25958 –25965
61. Kvam, E., Nannenga, B. L., Wang, M. S., Jia, Z., Sierks, M. R., and Messer,
A. (2009) Conformational targeting of fibrillar polyglutamine proteins in
live cells escalates aggregation and cytotoxicity. PLoS One 4, e5727
62. Nixon, R. A. (2013) The role of autophagy in neurodegenerative disease.
Nat. Med. 19, 983–997
63. Qi, L., and Zhang, X. D. (2014) Role of chaperone-mediated autophagy in
degrading Huntington’s disease-associated huntingtin protein. Acta
Biochim. Biophys. Sin. 46, 83–91
64. Au, A. K., Bayir, H., Kochanek, P. M., and Clark, R. S. (2010) Evaluation of
autophagy using mouse models of brain injury. Biochim. Biophys. Acta
1802, 918 –923
65. Juhász, G., Erdi, B., Sass, M., and Neufeld, T. P. (2007) Atg7-dependent
autophagy promotes neuronal health, stress tolerance, and longevity but is
dispensable for metamorphosis in Drosophila. Genes Dev. 21, 3061–3066
66. Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H.,
Zweckstetter, M., Outeiro, T. F., and Braus, G. H. (2012) Aggregate clearance of -synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. J. Biol. Chem.
287, 27567–27579
67. Miller-Fleming, L., Giorgini, F., and Outeiro, T. F. (2008) Yeast as a model
for studying human neurodegenerative disorders. Biotechnol. J. 3,
325–338
68. Gitler, A. D., Bevis, B. J., Shorter, J., Strathearn, K. E., Hamamichi, S., Su,

JOURNAL OF BIOLOGICAL CHEMISTRY

24833

Hsp31 Is a Stress Response Chaperone

69.

70.

71.

72.

73.

74.
75.

L. J., Caldwell, K. A., Caldwell, G. A., Rochet, J. C., McCaffery, J. M., Barlowe, C., and Lindquist, S. (2008) The Parkinson’s disease protein -synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U.S.A.
105, 145–150
Tenreiro, S., Reimão-Pinto, M. M., Antas, P., Rino, J., Wawrzycka, D.,
Macedo, D., Rosado-Ramos, R., Amen, T., Waiss, M., Magalhães, F.,
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